Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
4.880
-0.130 (-2.59%)
At close: May 8, 2026, 4:00 PM EDT
4.980
+0.100 (2.05%)
After-hours: May 8, 2026, 7:18 PM EDT
Quantum BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
28.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Kyntra Bio | 6.44M |
| Werewolf Therapeutics | 1.14M |
| IGC Pharma | 1.11M |
| Lisata Therapeutics | 170.00K |
| Senti Biosciences Holdings | 22.00K |
QNTM News
- 2 days ago - Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 - GlobeNewsWire
- 11 days ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 17 days ago - Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma submits Lucid-21-302 new drug application to the FDA - TheFly
- 5 weeks ago - Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly
- 5 weeks ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly
- 5 weeks ago - Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - GlobeNewsWire